Neurogastrx Overview

  • Founded
  • 2012

Founded
  • Status
  • Private

  • Employees
  • 17

Employees
  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $80M

  • Investors
  • 7

Neurogastrx General Information

Description

Developer of specialty therapies designed to treat gastrointestinal disorders affecting the enteric nervous system. The company's therapies address the unmet needs of functional and motility gastrointestinal disorders affecting gut contractions, sensation and the brain-gut axis, enabling the medical community to satisfy the unmet patient need and disease burden.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Pharmaceuticals
Primary Office
  • 600 Unicorn Park Drive
  • Woburn, MA 01801
  • United States
+1 (781) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurogastrx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 12-Jul-2021 $80M 00000 00000 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A) 01-Aug-2018 0000 000.00 0000 Completed Clinical Trials - Phase 2
1. Seed Round 12-Sep-2016 $2.75M $2.75M 00.000 Completed Clinical Trials - Phase 2
To view Neurogastrx’s complete valuation and funding history, request access »

Neurogastrx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 000,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Seed 1,363,633 $0.000100 6% $0.55 $0.55 1x $0.55 0.67%
To view Neurogastrx’s complete cap table history, request access »

Neurogastrx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of specialty therapies designed to treat gastrointestinal disorders affecting the enteric nervous system. The
Therapeutic Devices
Woburn, MA
17 As of 2023
00000
0000 0000-00-00
00000000000 00000

00000

usmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim venia
00000 0000000 000 00
San Diego, CA
0 As of 0000

000000

llum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proi
0000 000000000
00 As of 0000
00000
000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurogastrx Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aries Pharmaceuticals Corporation San Diego, CA 0
00000000 000000000 Venture Capital-Backed 00 00000 00000000000 00000
00000 000000 Formerly VC-backed Solana Beach, CA 0 0000 000000 - 000 0000
00000 000000000000 Formerly VC-backed Foster City, CA 000 00000 000000000 00000
0000000 Formerly VC-backed Fremont, CA 000 00000 000000 - 000 00000
You’re viewing 5 of 13 competitors. Get the full list »

Neurogastrx Patents

Neurogastrx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4126831-A1 Novel polymorphic forms of metopimazine Pending 02-Apr-2020 0000000000
US-11390620-B2 Polymorphic forms of metopimazine Active 02-Apr-2020 0000000000 00
US-10836757-B1 Polymorphic forms of metopimazine Active 02-Apr-2020 0000000000
US-20210323954-A1 Novel polymorphic forms of metopimazine Active 02-Apr-2020 0000000000
AU-2021246085-A1 Novel polymorphic forms of metopimazine Pending 02-Apr-2020 C07D417/06
To view Neurogastrx’s complete patent history, request access »

Neurogastrx Executive Team (7)

Name Title Board Seat Contact Info
Jim O'Mara President, Chief Executive Officer and Board Member
Cyril De Colle Ph.D Co-Founder, Board Member & Chief Scientific Officer
Paul Rogers Chief Commercial Officer
Christophe Arbet-Engels Ph.D Chief Medical Officer
James DeTore Chief Financial Officer
You’re viewing 5 of 7 executive team members. Get the full list »

Neurogastrx Board Members (6)

Name Representing Role Since
Aaron Royston MD venBio Board Member 000 0000
David Allison Ph.D 5AM Ventures Board Member 000 0000
Kevin Koch Ph.D OrbiMed Board Member 000 0000
Klaus Veitinger Ph.D OrbiMed Chairman 000 0000
You’re viewing 4 of 6 board members. Get the full list »

Neurogastrx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurogastrx Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Marshall Wace Hedge Fund Minority 000 0000 000000 0
RTW Investments Hedge Fund Minority 000 0000 000000 0
Samsara BioCapital Venture Capital Minority 000 0000 000000 0
Vivo Capital Venture Capital Minority 000 0000 000000 0
5AM Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »